Catheter Associated Urinary Tract Infections Treatment Market by Product Type, End-Users, & Geography (North America, Europe, Asia Pacific, Latin America, & MEA): Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2030

Description

Persistence Market Research has released a comprehensive report on the global market for Catheter Associated Urinary Tract Infections (CAUTI) treatment. This report provides a detailed assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, offering insights into the market structure. The publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global CAUTI treatment market from 2023 to 2033.

The global catheter associated urinary tract infections treatment market is forecast to expand at a CAGR of 4.0% and thereby increase from a value of US$1.4 Bn in 2023, to US$1.8 Bn by the end of 2030.

Key Insights:

Catheter Associated Urinary Tract Infections Treatment Market Size (2023E): US$1.4 Bn

Projected Market Value (2030F): US$1.8 Bn

Global Market Growth Rate (CAGR 2023 to 2030): 4.0%

Historical Market Growth Rate (CAGR 2018 to 2022): 5.0%

CAUTI Treatment Market - Report Scope:

The CAUTI treatment market is expected to witness substantial growth, driven by the increasing prevalence of urinary tract infections associated with catheter use. The market caters to various healthcare settings, including hospitals, clinics, and long-term care facilities, providing a range of treatment options. CAUTI treatment market growth is fueled by the rising awareness about infection prevention, advancements in catheter technologies, and the need for effective therapeutic interventions.

Market Growth Drivers:

Several key factors contribute to the growth of the global CAUTI treatment market. These include the growing incidence of urinary tract infections associated with catheter use, particularly in hospitalized patients. Advancements in catheter materials and designs aimed at reducing infection risks play a crucial role in driving market expansion. Additionally, the emphasis on infection control measures in healthcare facilities and the development of novel antimicrobial agents contribute to the market's positive outlook.

Market Restraints:

Despite promising growth prospects, the CAUTI treatment market faces challenges related to antibiotic resistance, limited treatment options, and the need for stringent infection prevention practices. The overuse of antibiotics and the emergence of resistant strains of bacteria pose significant hurdles in managing CAUTIs. Regulatory constraints and the complex nature of healthcare-associated infections also impact market penetration.

Market Opportunities:

The CAUTI treatment market presents significant growth opportunities driven by ongoing research, technological innovations, and collaborative efforts in infection prevention. The development of catheters with enhanced antimicrobial properties, the integration of digital health technologies for monitoring and early detection, and the emphasis on catheter care education create new avenues for market expansion. Strategic partnerships, investment in research and development, and the promotion of best practices in infection prevention are essential for capitalizing on emerging opportunities in this dynamic market.

Key Questions Answered in the Report:

What is the Forecast CAGR of the Catheter-Associated Urinary Tract Infections Treatment Market?
What was the Revenue Size of the Catheter-Associated Urinary Tract Infections Treatment Market in 2023?
Which Country Held the Largest Market Share in 2023?
Who are the Key Players in the Global Catheter-Associated Urinary Tract Infections Treatment Market?
Which is the Fastest-growing Segment of the Market by Indication Type?

Competitive Intelligence and Business Strategy:

Leading players in the global CAUTI treatment market focus on innovation, collaboration, and strategic investments to gain a competitive edge. Companies invest in R&D for developing catheters with advanced infection-resistant features and engage in partnerships with healthcare facilities to promote best practices in catheter care. Collaborations with regulatory bodies and educational institutions facilitate market access and ensure compliance with infection prevention guidelines. Moreover, patient education initiatives and awareness campaigns contribute to market growth and enhance patient outcomes in the evolving landscape of CAUTI treatment.

Key Companies Profiled:
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline (GSK)
AstraZeneca
Bayer AG
Johnson & Johnson
Novartis International AG
Sanofi
Roche Holding AG
Eli Lilly and Company
Bristol-Myers Squibb Company
Abbott Laboratories
Astellas Pharma Inc.
Boehringer Ingelheim

Daiichi Sankyo Company, Limited

Gilead Sciences, Inc.
Mylan N.V.

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

CAUTI Treatment Market Research Segmentation:

Quinolones lead the catheter-associated urinary tract infections (CAUTIs) treatment market, driven by their broad antibacterial activity and proven efficacy against urinary tract pathogens, exemplified by ciprofloxacin and levofloxacin. These antibiotics inhibit bacterial DNA gyrase, crucial for DNA replication. Nitrofurantoin is the fastest-growing category due to its effectiveness against common urinary pathogens, particularly Escherichia coli. Its targeted action in the urinary tract makes it a efficient treatment for CAUTIs.

Symptomatic CAUTI (Bacteremic) dominates due to clinical severity and the urgent need for effective interventions. Immediate treatment is crucial to prevent complications, including sepsis. Asymptomatic CAUTI (Bacteriuria) is the fastest-growing category, emphasizing preventive strategies and understanding its role in the reservoir of resistant bacteria. Hospital pharmacies hold the largest share, being primary access points for CAUTI diagnosis and treatment. They play a central role in providing comprehensive pharmaceutical services. Online drug stores are the fastest-growing category, reflecting the shift towards convenient healthcare access through user-friendly interfaces.

Europe leads in the CAUTIs treatment market due to advanced healthcare infrastructure, robust research initiatives, and collaborations between academia, healthcare institutions, and pharmaceutical companies. The region's focus on innovation and continuous advancements solidifies its dominance in shaping effective treatment approaches.

In summary, quinolones dominate due to their broad antibacterial activity, while nitrofurantoin is the fastest-growing category. Symptomatic CAUTI (Bacteremic) is the major indication type, highlighting the urgency in treating severe cases. Hospital pharmacies are the largest distribution channel, and Europe leads in CAUTIs treatment, emphasizing innovation and research collaborations.

By Drug Type:
Penicillin & Combinations
Quinolones
Cephalosporin
Aminoglycoside Antibiotics

Sulphonamides (Sulfamethoxazole +Trimethoprim)

Azoles and Amphotericin B
Tetracycline (Doxycycline)
Nitrofura
By Indication Type:

Asymptomatic CAUTI (Bacteriuria)

Symptomatic CAUTI (Bacteremic)

By Distribution Channel:
Hospital Pharmacies

Gynaecology and Urology Clinics

Drug Stores
Retail Pharmacies
Online Drug Stores
By Region:
North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Product Code: PMRREP33711

1. Executive Summary

1.1. Global Catheter-Associated Urinary Tract Infections Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations

2. Market Overview

2.1. Market Scope and Definition
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Opportunity
- 2.2.4. Challenges
- 2.2.5. Key Trends
2.3. Drug Type Lifecycle Analysis
2.4. Catheter-Associated Urinary Tract Infections Treatment Market: Value Chain
- 2.4.1. List of Raw Material Supplier
- 2.4.2. List of Manufacturers
- 2.4.3. List of Distributors
- 2.4.4. List of Distribution Channels
- 2.4.5. Profitability Analysis
2.5. Porter Five Force's Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
- 2.7.1. Global Sectorial Outlook
- 2.7.2. Global GDP Growth Outlook
- 2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Technology Landscape

3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

3.1. Key Highlights
- 3.1.1. Market Volume (Units) Projections
- 3.1.2. Market Size and Y-o-Y Growth
- 3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
- 3.2.1. Historical Market Size Analysis, 2013-2016
- 3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Drug Type
- 3.3.1. Introduction / Key Findings
- 3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Drug Type, 2018 - 2022
- 3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
  - 3.3.3.1. Penicillin & Combinations
  - 3.3.3.2. Quinolones
  - 3.3.3.3. Cephalosporin
  - 3.3.3.4. Aminoglycoside Antibiotics
  - 3.3.3.5. Sulphonamides
  - 3.3.3.6. Azoles and Amphotericin B
  - 3.3.3.7. Tetracycline
  - 3.3.3.8. Nitrofurans
  - 3.3.3.9. Other
3.4. Market Attractiveness Analysis: Drug Type
3.5. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Indication Type
- 3.5.1. Introduction / Key Findings
- 3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Indication Type, 2018 - 2022
- 3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
  - 3.5.3.1. Asymptomatic CAUTI (Bacteriuria)
  - 3.5.3.2. Symptomatic CAUTI (Bacteremic)
3.6. Market Attractiveness Analysis: Indication Type
3.7. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Distribution Channel
- 3.7.1. Introduction / Key Findings
- 3.7.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
- 3.7.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
  - 3.7.3.1. Hospital Pharmacies
  - 3.7.3.2. Gynaecology and Urology Clinics
  - 3.7.3.3. Drug Stores
  - 3.7.3.4. Retail Pharmacies
  - 3.7.3.5. Online Drug Stores
3.8. Market Attractiveness Analysis: Distribution Channel

4. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Region

4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
- 4.3.1. North America
- 4.3.2. Europe
- 4.3.3. East Asia
- 4.3.4. South Asia & Pacific
- 4.3.5. Latin America
- 4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region

5. North America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 5.3.1. By Country
- 5.3.2. By Drug Type
- 5.3.3. By Indication Type
- 5.3.4. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 5.4.1. U.S.
- 5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
- 5.5.1. Penicillin & Combinations
- 5.5.2. Quinolones
- 5.5.3. Cephalosporin
- 5.5.4. Aminoglycoside Antibiotics
- 5.5.5. Sulphonamides
- 5.5.6. Azoles and Amphotericin B
- 5.5.7. Tetracycline
- 5.5.8. Nitrofurans
- 5.5.9. Other
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
- 5.6.1. Asymptomatic CAUTI (Bacteriuria)
- 5.6.2. Symptomatic CAUTI (Bacteremic)
5.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 5.7.1. Hospital Pharmacies
- 5.7.2. Gynaecology and Urology Clinics
- 5.7.3. Drug Stores
- 5.7.4. Retail Pharmacies
- 5.7.5. Online Drug Stores
5.8. Market Attractiveness Analysis

6. Europe Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 6.3.1. By Country
- 6.3.2. By Drug Type
- 6.3.3. By Indication Type
- 6.3.4. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 6.4.1. Germany
- 6.4.2. France
- 6.4.3. U.K.
- 6.4.4. Italy
- 6.4.5. Spain
- 6.4.6. Russia
- 6.4.7. Turkey
- 6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
- 6.5.1. Penicillin & Combinations
- 6.5.2. Quinolones
- 6.5.3. Cephalosporin
- 6.5.4. Aminoglycoside Antibiotics
- 6.5.5. Sulphonamides
- 6.5.6. Azoles and Amphotericin B
- 6.5.7. Tetracycline
- 6.5.8. Nitrofurans
- 6.5.9. Other
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
- 6.6.1. Asymptomatic CAUTI (Bacteriuria)
- 6.6.2. Symptomatic CAUTI (Bacteremic)
6.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 6.7.1. Hospital Pharmacies
- 6.7.2. Gynaecology and Urology Clinics
- 6.7.3. Drug Stores
- 6.7.4. Retail Pharmacies
- 6.7.5. Online Drug Stores
6.8. Market Attractiveness Analysis

7. East Asia Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 7.3.1. By Country
- 7.3.2. By Drug Type
- 7.3.3. By Indication Type
- 7.3.4. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 7.4.1. China
- 7.4.2. Japan
- 7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
- 7.5.1. Penicillin & Combinations
- 7.5.2. Quinolones
- 7.5.3. Cephalosporin
- 7.5.4. Aminoglycoside Antibiotics
- 7.5.5. Sulphonamides
- 7.5.6. Azoles and Amphotericin B
- 7.5.7. Tetracycline
- 7.5.8. Nitrofurans
- 7.5.9. Other
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
- 7.6.1. Asymptomatic CAUTI (Bacteriuria)
- 7.6.2. Symptomatic CAUTI (Bacteremic)
7.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 7.7.1. Hospital Pharmacies
- 7.7.2. Gynaecology and Urology Clinics
- 7.7.3. Drug Stores
- 7.7.4. Retail Pharmacies
- 7.7.5. Online Drug Stores
7.8. Market Attractiveness Analysis

8. South Asia & Pacific Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 8.3.1. By Country
- 8.3.2. By Drug Type
- 8.3.3. By Indication Type
- 8.3.4. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 8.4.1. India
- 8.4.2. Southeast Asia
- 8.4.3. ANZ
- 8.4.4. Rest of South Asia & Pacific
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
- 8.5.1. Penicillin & Combinations
- 8.5.2. Quinolones
- 8.5.3. Cephalosporin
- 8.5.4. Aminoglycoside Antibiotics
- 8.5.5. Sulphonamides
- 8.5.6. Azoles and Amphotericin B
- 8.5.7. Tetracycline
- 8.5.8. Nitrofurans
- 8.5.9. Other
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
- 8.6.1. Asymptomatic CAUTI (Bacteriuria)
- 8.6.2. Symptomatic CAUTI (Bacteremic)
8.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 8.7.1. Hospital Pharmacies
- 8.7.2. Gynaecology and Urology Clinics
- 8.7.3. Drug Stores
- 8.7.4. Retail Pharmacies
- 8.7.5. Online Drug Stores
8.8. Market Attractiveness Analysis

9. Latin America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 9.3.1. By Country
- 9.3.2. By Drug Type
- 9.3.3. By Indication Type
- 9.3.4. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
- 9.5.1. Penicillin & Combinations
- 9.5.2. Quinolones
- 9.5.3. Cephalosporin
- 9.5.4. Aminoglycoside Antibiotics
- 9.5.5. Sulphonamides
- 9.5.6. Azoles and Amphotericin B
- 9.5.7. Tetracycline
- 9.5.8. Nitrofurans
- 9.5.9. Other
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
- 9.6.1. Asymptomatic CAUTI (Bacteriuria)
- 9.6.2. Symptomatic CAUTI (Bacteremic)
9.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 9.7.1. Hospital Pharmacies
- 9.7.2. Gynaecology and Urology Clinics
- 9.7.3. Drug Stores
- 9.7.4. Retail Pharmacies
- 9.7.5. Online Drug Stores
9.8. Market Attractiveness Analysis

10. Middle East & Africa Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)

10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
- 10.3.1. By Country
- 10.3.2. By Drug Type
- 10.3.3. By Indication Type
- 10.3.4. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
- 10.4.1. GCC
- 10.4.2. Egypt
- 10.4.3. South Africa
- 10.4.4. Northern Africa
- 10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Drug Type, 2023 - 2030
- 10.5.1. Penicillin & Combinations
- 10.5.2. Quinolones
- 10.5.3. Cephalosporin
- 10.5.4. Aminoglycoside Antibiotics
- 10.5.5. Sulphonamides
- 10.5.6. Azoles and Amphotericin B
- 10.5.7. Tetracycline
- 10.5.8. Nitrofurans
- 10.5.9. Other
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Indication Type, 2023 - 2030
- 10.6.1. Asymptomatic CAUTI (Bacteriuria)
- 10.6.2. Symptomatic CAUTI (Bacteremic)
10.7. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
- 10.7.1. Hospital Pharmacies
- 10.7.2. Gynaecology and Urology Clinics
- 10.7.3. Drug Stores
- 10.7.4. Retail Pharmacies
- 10.7.5. Online Drug Stores
10.8. Market Attractiveness Analysis

11. Competition Landscape

11.1. Market Share Analysis, 2022
11.2. Market Structure
- 11.2.1. Competition Intensity Mapping By Market
- 11.2.2. Competition Quinolones
- 11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
- 11.3.1. Pfizer Inc.
  - 11.3.1.1. Overview
  - 11.3.1.2. Segments and Product
  - 11.3.1.3. Key Financials
  - 11.3.1.4. Market Developments
  - 11.3.1.5. Market Strategy
- 11.3.2. Merck & Co., Inc.
  - 11.3.2.1. Overview
  - 11.3.2.2. Segments and Product
  - 11.3.2.3. Key Financials
  - 11.3.2.4. Market Developments
  - 11.3.2.5. Market Strategy
- 11.3.3. GlaxoSmithKline (GSK)
  - 11.3.3.1. Overview
  - 11.3.3.2. Segments and Product
  - 11.3.3.3. Key Financials
  - 11.3.3.4. Market Developments
  - 11.3.3.5. Market Strategy
- 11.3.4. AstraZeneca
  - 11.3.4.1. Overview
  - 11.3.4.2. Segments and Product
  - 11.3.4.3. Key Financials
  - 11.3.4.4. Market Developments
  - 11.3.4.5. Market Strategy
- 11.3.5. Bayer AG
  - 11.3.5.1. Overview
  - 11.3.5.2. Segments and Product
  - 11.3.5.3. Key Financials
  - 11.3.5.4. Market Developments
  - 11.3.5.5. Market Strategy
- 11.3.6. Johnson & Johnson
  - 11.3.6.1. Overview
  - 11.3.6.2. Segments and Product
  - 11.3.6.3. Key Financials
  - 11.3.6.4. Market Developments
  - 11.3.6.5. Market Strategy
- 11.3.7. Novartis International AG
  - 11.3.7.1. Overview
  - 11.3.7.2. Segments and Product
  - 11.3.7.3. Key Financials
  - 11.3.7.4. Market Developments
  - 11.3.7.5. Market Strategy
- 11.3.8. Sanofi
  - 11.3.8.1. Overview
  - 11.3.8.2. Segments and Product
  - 11.3.8.3. Key Financials
  - 11.3.8.4. Market Developments
  - 11.3.8.5. Market Strategy
- 11.3.9. Roche Holding AG
  - 11.3.9.1. Overview
  - 11.3.9.2. Segments and Product
  - 11.3.9.3. Key Financials
  - 11.3.9.4. Market Developments
  - 11.3.9.5. Market Strategy
- 11.3.10. Eli Lilly and Company
  - 11.3.10.1. Overview
  - 11.3.10.2. Segments and Product
  - 11.3.10.3. Key Financials
  - 11.3.10.4. Market Developments
  - 11.3.10.5. Market Strategy
- 11.3.11. Bristol-Myers Squibb Company
  - 11.3.11.1. Overview
  - 11.3.11.2. Segments and Product
  - 11.3.11.3. Key Financials
  - 11.3.11.4. Market Developments
  - 11.3.11.5. Market Strategy
- 11.3.12. Abbott Laboratories
  - 11.3.12.1. Overview
  - 11.3.12.2. Segments and Product
  - 11.3.12.3. Key Financials
  - 11.3.12.4. Market Developments
  - 11.3.12.5. Market Strategy
- 11.3.13. Astellas Pharma Inc.
  - 11.3.13.1. Overview
  - 11.3.13.2. Segments and Product
  - 11.3.13.3. Key Financials
  - 11.3.13.4. Market Developments
  - 11.3.13.5. Market Strategy
- 11.3.14. Boehringer Ingelheim
  - 11.3.14.1. Overview
  - 11.3.14.2. Segments and Product
  - 11.3.14.3. Key Financials
  - 11.3.14.4. Market Developments
  - 11.3.14.5. Market Strategy
- 11.3.15. Daiichi Sankyo Company, Limited
  - 11.3.15.1. Overview
  - 11.3.15.2. Segments and Product
  - 11.3.15.3. Key Financials
  - 11.3.15.4. Market Developments
  - 11.3.15.5. Market Strategy
- 11.3.16. Gilead Sciences, Inc.
  - 11.3.16.1. Overview
  - 11.3.16.2. Segments and Product
  - 11.3.16.3. Key Financials
  - 11.3.16.4. Market Developments
  - 11.3.16.5. Market Strategy
- 11.3.17. Mylan N.V.
  - 11.3.17.1. Overview
  - 11.3.17.2. Segments and Product
  - 11.3.17.3. Key Financials
  - 11.3.17.4. Market Developments
  - 11.3.17.5. Market Strategy
- 11.3.18. Teva Pharmaceutical Industries Ltd.
  - 11.3.18.1. Overview
  - 11.3.18.2. Segments and Product
  - 11.3.18.3. Key Financials
  - 11.3.18.4. Market Developments
  - 11.3.18.5. Market Strategy
- 11.3.19. Sun Pharmaceutical Industries Ltd.
  - 11.3.19.1. Overview
  - 11.3.19.2. Segments and Product
  - 11.3.19.3. Key Financials
  - 11.3.19.4. Market Developments
  - 11.3.19.5. Market Strategy

12. Appendix

12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations